News From CanRIO

CanRIO Researcher Awarded an Arthritis Society of Canada Grant!

Posted June 1, 2023
Congratulations to Dr. Marie Hudson who has been awarded a Arthritis Society of Canada grant to study the mechanisms underlying rheumatic immune related adverse events! Using a large bank of tissue samples from people with cancer who were treated with immune checkpoint inhibitors, Dr. Hudson’s team will compare these cell… Read More

CanRIO Researchers Awarded a 2023 CIORA Grant!

Posted June 1, 2023
Congratulations to Dr. Shahin Jamal and Dr. Tom Appleton on receiving a Canadian Initiative for Outcomes in Rheumatology cAre (CIORA) grant from the Canadian Rheumatology Association Foundation (CRAF)! They are leading the study on Early Adalimumab Induction for Treatment of Steroid-Dependent Checkpoint Inhibitor Associated Inflammatory Arthritis: A Pragmatic Randomized Clinical… Read More

Introducing our CanRIO Twitter account!

Posted June 1, 2023
We are pleased to share our new Twitter account! @CanRIO_Tweets Keep connected and updated with news, research, initiatives, and collaborations! Check out the link below.… Read More

First international case rounds in the books!

Posted June 1, 2023
Our first international case rounds was held on February 28th, 2023 with Dr. Marie Kostine as our featured researcher. Rounds were well attended by colleagues from across Canada, the United States and Europe. Interesting discussions arose regarding differences in the biologic management of ICI-induced inflammatory arthritis which varies based… Read More

Welcome to

Posted June 1, 2023
CanRIO is thrilled to launch the first educational website dedicated to the rheumatic complications of immunotherapy. We hope that this website will serve as an educational resource to rheumatologists, oncologists and all healthcare providers who care for cancer patients receiving immunotherapy. Read More

Hot off the Press!

Posted June 1, 2023
CanRIO has just published its second national case series. This retrospective cohort study included 27 patients with pre-existing autoimmune disease (PAD) treated with immunotherapy. Consistent with previously published studies, PAD exacerbations were common, however generally mild and manageable. Compared to our Canadian cohort without PAD, there were higher rates of… Read More